Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salvatore Del Prete

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Expert Review of Anticancer Therapy|October 26, 2012
Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinomaDaniele Santini, Raffaele Addeo, Bruno Vincenzi, et al.
CNS Oncology|July 11, 2019
Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter studyRaffaele Addeo, Giuseppe Lamberti, Giorgia Simonetti, et al.
Critical Reviews in Oncology/Hematology|September 9, 2008
Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patientsFabio Puglisi, Laura Deroma, Stefania Russo, et al.
Cancer Chemotherapy and Pharmacology|October 9, 2007
Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of ageRaffaele Addeo, Vincenzo Faiola, Rosario Guarrasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and toleranceRaffaele Addeo, Michele Caraglia, Sergio Bellini, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studiesGiovanni Vitale, Giovanni Lupoli, Rosario Guarrasi, et al.
Anticancer Research|May 17, 2002
Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI)Claudia Pizzi, Michele Caraglia, Maria Cianciulli, et al.
Journal of Neuro-Oncology|August 10, 2010
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastomaRaffaele Addeo, Michele Caraglia, M Serena De Santi, et al.
Clinical Colorectal Cancer|April 26, 2006
Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experienceVittorio Gebbia, Salvatore Del Prete, Nicolò Borsellino, et al.
Future Oncology (London, England)|October 27, 2016
Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life studySalvatore Del Prete, Gregorio Cennamo, Luigi Leo, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Expert Review of Anticancer Therapy|October 26, 2012
Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinomaDaniele Santini, Raffaele Addeo, Bruno Vincenzi, et al.
CNS Oncology|July 11, 2019
Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter studyRaffaele Addeo, Giuseppe Lamberti, Giorgia Simonetti, et al.
Critical Reviews in Oncology/Hematology|September 9, 2008
Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patientsFabio Puglisi, Laura Deroma, Stefania Russo, et al.
Cancer Chemotherapy and Pharmacology|October 9, 2007
Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of ageRaffaele Addeo, Vincenzo Faiola, Rosario Guarrasi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and toleranceRaffaele Addeo, Michele Caraglia, Sergio Bellini, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studiesGiovanni Vitale, Giovanni Lupoli, Rosario Guarrasi, et al.
Anticancer Research|May 17, 2002
Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI)Claudia Pizzi, Michele Caraglia, Maria Cianciulli, et al.
Journal of Neuro-Oncology|August 10, 2010
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastomaRaffaele Addeo, Michele Caraglia, M Serena De Santi, et al.
Clinical Colorectal Cancer|April 26, 2006
Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experienceVittorio Gebbia, Salvatore Del Prete, Nicolò Borsellino, et al.
Future Oncology (London, England)|October 27, 2016
Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life studySalvatore Del Prete, Gregorio Cennamo, Luigi Leo, et al.
Pageof 8